UPDATE: Did Abiomed fly too close to the sun?

Mass Device

Abiomed's dilemma is of its own making, Jefferies & Co. analyst Raj Denhoy tells MassDevice.com.

UPDATED Dec. 14, 2012, at 10:30 a.m.

Abiomed [1] (NSDQ:ABMD [2]) is impaled on the prongs of a 3-horned dilemma with its flagship Impella heart pump, and it's a problem of it's own making, according to 1 Wall Street analyst.

Last week the federal watchdog agency's Circulatory Devices Advisory panel ruled that some cardiovascular pump makers, including Danvers, Mass.-based Abiomed, must submit already-approved medical devices for review under the more-stringent pre-market approval pathway. The various Impella devices can stay on the U.S. market in the meantime.

Although the panel acknowledged that non-roller-type cardiopulmonary bypass blood pumps are life-supporting, it recommended against shifting them to a lower-risk category for temporary ventricular support. The decision [3] sent ABMD shares spiraling downward Dec. 7 [4], dropping as low as $12 per share in morning trading before closing at $12.49 apiece, down 3.0%.

Source URL (retrieved on *01/31/2015 - 2:36am*):
http://www.mdtmag.com/news/2012/12/update-did-abiomed-fly-too-close-sun?qt-video_of_the_day=0&qt-most_popular=0

Links:
[1] http://www.massdevice.com/company/abiomed-inc
[2] http://www.google.com/finance?q=abmd
[3] http://www.massdevice.com/news/fda-panel-decision-means-abiomed-will-need-new-pma-impella-pump/
[4] http://www.massdevice.com/news/abiomed-shares-sink-fda-votes-keep-impella-pump-highest-risk-level?page=show